Business Wire

China's Online Mutual Aid Market Expected to Triple to 450 Million Users by 2025

7.5.2020 10:39:00 EEST | Business Wire | Press release

Share

By 2025, China's online mutual aid industry is expected to reach 450 million users, or nearly 32% of the country’s population, three times the number of current users, according to the Online Mutual Aid Industry White Paper published today by the Research Institute of Ant Group (“the Institute”).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200507005383/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

White Paper Predicts Chinese Online Mutual Aid Market to Triple by 2025 (Graphic: Busness Wire)

The industry white paper, the first of its kind in China, surveyed over 58,000 users of online mutual aid on their perceptions of the industry. Nearly 80% of the respondents felt that online mutual aid platforms strengthened their sense of security. Over 53% also stated that they would consider enrolling their family members in online mutual aid programs.

Users of online mutual aid programs in China are primarily from low-income or middle-income households, according to the white paper. Among those surveyed, who took part in March this year by responding to an online questionnaire, 80% earn less than RMB 8,333 (USD 1,180) per month while 72% come from third or lower-tier cities and rural areas.

“Online mutual aid platforms have become a complementary force in China’s comprehensive healthcare system, which is comprised of both essential public coverage for all citizens and commercial health insurance,” said Zheng Bingwen, Director of the World Social Security Center at the Chinese Academy of Social Sciences and one of the advisers to the white paper.

The reimbursement rate of China’s serious disease insurance scheme, part of the public healthcare system, is capped at 60%1, leaving a portion that patients still need to pay themselves. According to the white paper, online mutual aid programs serve as a complement by further reducing out-of-pocket expenses accrued in the treatment of critical illnesses, bringing it from 40% to below 20% for patients solely dependent on public healthcare coverage.

The white paper estimates that more than 150 million users had enrolled in various online mutual aid programs in China as of the end of 2019, of which over 100 million use Xiang Hu Bao, the online mutual aid platform housed on Alipay, the world's leading open digital lifestyle platform.

Amid the Covid-19 outbreak, Xiang Hu Bao in February also introduced a temporary one-time protection scheme free of charge for all participants, offering a payout of up to RMB 100,000 (USD 14,000) if someone who takes part passes away from the infection. Payouts were entirely borne by Ant Group and Xiang Hu Bao participants did not need to bear the cost.

“As awareness and concerns about health-care needs grows in China, especially since the Covid-19 outbreak, public demand for more comprehensive and diversified healthcare coverage will continue to rise,” said Ming Yin, Vice President of Ant Group. “Online mutual aid platforms will have an increasingly important role to play in providing a basic health plan for people, who can then choose from a wide range of healthcare services and policies.”

“We are committed to serving more users across China and providing them with inclusive mutual aid programs tailored to their specific needs,” Mr. Yin said.

While nearly 70% of online mutual aid participants surveyed in the white paper said they were not covered by commercial health insurance, over 42% said they intend to purchase such insurance products in the future.

This finding is in line with a survey conducted by FT Confidential Research2 in June 2019, which found that 33% of Xiang Hu Bao’s participants intended to buy a critical illness insurance product over the next six months, versus only 22% of those who do not use the platform.

About Xiang Hu Bao

Xiang Hu Bao, which literally means “mutual protection,” was launched in October 2018 and provides its participants with a basic health plan covering 100 types of critical illness, including thyroid cancer, breast cancer, lung cancer, critical brain injury and acute myocardial infarction. All participants equally share the risk of becoming critically ill and collectively bear the related medical expenses. On the Xiang Hu Bao platform, the entire evidence submission process is powered by Alipay’s proprietary consortium blockchain technology, which ensures the process is tamper-proof and helps to increase the platform’s transparency, differentiating itself from other mutual aid platforms. While Xiang Hu Bao is not a health insurance product, it complements premium health insurance offerings in the market that have a wider range and depth of coverage.

About Alipay

Alipay is the world's leading open digital lifestyle platform operated by Ant Financial Services Group (Ant Group). In 2004, Alipay launched as an escrow service to address the issue of trust between online buyers and sellers in the early days of e-commerce in China. Continuously innovating to bring mobile payment to the world, Alipay serves more than 1.2 billion users worldwide together with its global e-wallet partners as of June 30, 2019. Alipay has evolved from a payment tool to become a one-stop digital lifestyle platform. Through an open platform strategy, it introduces service providers from sectors such as local living, public services, and financial services, to bring consumers a more comprehensive experience. Along the way, it helps merchants digitalize their operations, promoting digital transformation in the service industry.

Alipay actively shares its financial technology experience with overseas partners, in order to bring inclusive financial services to the world. Working with more than 250 overseas financial institutions, Alipay created online payment channels for buyers and sellers in more than 200 countries and regions. When Chinese people travel abroad, they can pay directly using their mobile phones, and receive dedicated local merchant services through Alipay. These services have been introduced in 56 countries and regions. Tax reimbursement via Alipay is supported in 35 countries and regions, and Alipay supports 27 different currencies. In addition, foreign tourists and foreigners living in China can also use Alipay for mobile payments in the country.

1 Source: http://www.xinhuanet.com/english/2019-05/12/c_138052821.htm

2 Source: https://www.ft.com/content/3bbf683e-a325-11e9-974c-ad1c6ab5efd1

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Enquiries
Bell Wang
E: yixing.wl@antfin.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OdysseyRe Announces New Co-Chief Underwriting Officers for EMEA18.5.2026 10:00:00 EEST | Press release

Odyssey Reinsurance Company (OdysseyRe) today announced the appointments of Tegwen Gromellon and Anne-Claire Serres as co-chief underwriting officers of its EMEA division, effective July 1. They succeed longtime Chief Underwriting Officer, Gaël Le Païh, who is retiring later this year following 36 years with the Company. Based in Paris, Serres joined OdysseyRe in 2018 as the market director for France and will lead the division’s business across France, Africa and the Middle East. Gromellon, who joined OdysseyRe in 2004, has served as market director for Germany, Austria, Benelux and Switzerland since 2019. He will take the lead for the rest of Europe, including the relationship with the Company’s representative office in Stockholm for the Nordic markets and across Turkey. “We are delighted to appoint both Tegwen and Anne-Claire to these important leadership positions,” said Isabelle Dubots-Lafitte, chief executive officer of EMEA for OdysseyRe. “These appointments recognize their sign

Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy18.5.2026 10:00:00 EEST | Press release

Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, today announced safety and antitumour efficacy results from an interim review of the ongoing Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer (NMIBC) patients. These data were shared via an oral podium presentation at the American Urology Association (AUA26) Annual Meeting. Prokarium CMO, Dr Josefin-Beate Holz said “These data demonstrate ZH9 as a universally applicable treatment for patients. As the treatment is very well tolerated and is showing impactful outcomes for early and BCG-non-responsive patients alike, it opens up the potential for ZH9 to be a transformative bladder saving treatment.” "There is a clear and urgent need to move beyond BCG. The current treatment burden—requiring up to 18 catheterisations in the first year— detrimentally impacts real-world compliance and patient outcomes," said Ibs Mahmood, CEO of Prokarium. "Pat

Arboris Capital Selects ROYC to Expand Private Markets Capabilities on CapGain Platform18.5.2026 10:00:00 EEST | Press release

Arboris Capital Limited (“Arboris”), a DIFC-based firm arranging alternative investments, authorised by the Dubai Financial Services Authority (DFSA), today announced that it has selected ROYC AB (“ROYC”), a private markets technology and infrastructure provider, to support the continued development of its private markets offering through its platform, CapGain. In its ongoing efforts to expand its private markets capabilities across the Middle East, Arboris has undertaken a strategic review of how to further scale its offering while maintaining the integrity of its existing platform. As a result, Arboris has chosen to integrate ROYC’s fund access, sourcing, and structuring capabilities into CapGain, complementing its existing infrastructure. CapGain is Arboris’s proprietary investment platform, purpose-built to facilitate access between international private market opportunities and Professional Investors in the region. CapGain provides fully digital investor onboarding and KYC, a secu

LogicMonitor and Deutsche Telekom Expand Partnership Across Europe18.5.2026 10:00:00 EEST | Press release

LogicMonitor®, the AI-first platform for Autonomous IT, today announced the expanded availability of its platform within Deutsche Telekom’s managed services portfolio across selected European markets, including DACH, Benelux, and the Nordics. The expansion builds on operational use of LogicMonitor in the United Kingdom since 2023, where it has supported Deutsche Telekom’s service teams in improving visibility across network, cloud, and hybrid infrastructure environments. Experience gained from these deployments is now informing broader service enablement across additional European markets. As enterprise IT environments grow more complex, organisations require more than visibility—they need predictive resilience. Through defined use cases, LogicMonitor complements Deutsche Telekom’s existing service management, monitoring, and security tooling, helping teams anticipate, detect, and resolve issues before they impact business operations. In the United Kingdom, the partnership has delivere

VahatiCor Appoints Harry D. Rowland, Ph.D., as Chief Executive Officer18.5.2026 09:00:00 EEST | Press release

VahatiCor, Inc., a medtech company developing interventional therapies for Coronary Microvascular Dysfunction (CMD), announced today the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517830314/en/ VahatiCor CEO, Harry D. Rowland, Ph.D. Rowland previously served as Chief Executive Officer and President of Endotronix, where he led the development and commercialization of the Cordella™ Pulmonary Artery Sensor and Heart Failure System. Under his leadership, Endotronix raised over $150 million and grew to more than 150 employees. He also oversaw the PROACTIVE-HF pivotal trial from execution through FDA premarket approval and commercial launch. Following its acquisition by Edwards Lifesciences in 2024, Rowland stayed on to support key CMS national coverage and CE Mark milestones. "Harry has led a medical company through this arc before. He took Endotronix from

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye